Xavron

early empirical therapy for acute stroke or lateral amyotrophic sclerosis

Xavron is a Ukrainian generic drug1 identical to the original Japanese medicinal product Radicut/Radicava.
Radicut® was approved by FDA in 2017 in the USA as Radicava® for treatment amyotrophic lateral sclerosis. Active substance of Xavron – edaravone – is included in the Japanese Protocol for the treatment of acute ischemic stroke.2 Xavron – 20 ml of solution contains 30 mg of edaravone.

Indications:

  1. Improvement of neurological symptoms, disorders of activities of daily living, and functional disorders associated with acute ischemic stroke.
  2. Inhibition of progression of functional disorder in patients with amyotrophic lateral sclerosis.
Learn more

Literature:

1. Державний реєстр лікарських засобів України: www.drlz.com.ua

2. Kern R. Comparison of the European and Japanese guidelines for the management of ischemic stroke / R. Kern, M. Nagayama, K. Toyoda // Cerebrovasc Dis., 2013;35:402-418

Xavron will be useful in:

Ischemic stroke

Ischemic stroke is an acute disorder of cerebral circulation due to deficiency of delivery of arterial blood to the brain, which leads to its hypoxia and development of areas of necrosis.

Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a rare incurable slowly progressive degenerative disease of the central nervous system with the lesion of upper and lower motor neurons.